ideally be active against urogenital and extragenital infections. Notably, GARDP is one of the few entities working in partner ship with a small and mediumsized enterprise, Entasis Therapeutics, in the late-stage development of a novel, first-in-class treatment for gonorrhoea. A phase 3 clinical trial is due to commence in 2019.
The neonatal sepsis programme aims to deliver an empirical treatment for infections by drug-resistant, Gram-negative bacteria and develop a treatment for infections in which the causative pathogen is confirmed to be multidrug resistant (eg, carbapenemase-producing Enterobacteriaceae). GARDP's global observational study to understand the clinical management and treatment of sepsis in neonates will inform the development of optimised treatment regimens. A development programme for fosfomycin has commenced with a phase 2 pharmacokinetic and safety study in neonates currently underway (NCT03453177).
GARDP's paediatric antibiotic platform to expedite development of new and late-stage pipeline drugs has recently been approved. It aims to extend use, improve or optimise formulations of existing antibiotics for use in childhood infections, support the updating of paediatric evidence-based treatment guidelines, and develop an international neonatal and paediatric clinical trial network.
GARDP's transversal research and development programme comprises two elements. The memory recovery component aims to champion a new generation of antimicrobial research and development researchers by connecting this community via REVIVE, a website with open access to numerous resources including bespoke webinars. The memory recovery component is also identifying undeveloped or forgotten antibiotics that could be developed into new treatments. The exploratory component aims to build a portfolio of novel chemical entities or drugs, including drug combinations, to support GARDP's clinical programmes.
GARDP is working with others in the global landscape of research and development of new antibiotics, including CARB-X, The Pew Charitable Trusts, Novo REPAIR Impact Fund, Joint Programming Initiative on Antimicrobial Resistance, and the Wellcome Trust, and with societies including British Society for Antimicrobial Chemotherapy, European Society of Clinical Microbiology and Infectious Diseases, and American Society for Microbiology to copromote activities as well as co-organise conferences and symposia.
GARDP's rapid evolution since 2016 highlights that a not-for-profit, public health focused model can offer a realistic alternative to commercial drug development and is an important component of the antibiotic research and development landscape.
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For REVIVE see https://www. revive.gardp.org
